文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

细胞周期阻滞生物标志物联合经典急性肾损伤标志物的应用

Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论在无2-3期急性肾损伤患者中,尿[TIMP-2]•[IGFBP7]>2.0联合1期尿量或血肌酐标准可显著提高对1周内严重急性肾损伤或死亡的预测风险分层。

该研究为Sapphire研究的事后分析,前瞻性纳入无急性肾损伤KDIGO 2期或3期的患者,探讨在少尿和/或氮质血症情况下细胞周期阻滞生物标志物联合传统指标对预测严重急性肾损伤(需肾脏替代治疗或尿量、血肌酐变化)或死亡的價值。主要终点为1周内发生严重急性肾损伤或死亡,79例达到主要终点。1期尿量、血肌酐及尿[TIMP-2]•[IGFBP7]>2.0均独立于非肾脏APACHE III评分预测主要终点,联合预测因子使风险比从2.17增至4.14再至10.05。在1期急性肾损伤时,即使7天内未进展至2-3期,[TIMP-2]•[IGFBP7]>2.0仍与9个月死亡或透析风险增加相关。

要点

  • 在无KDIGO 2-3期急性肾损伤患者中,1期尿量标准、血肌酐标准及尿[TIMP-2]•[IGFBP7]>2.0均独立于非肾脏APACHE III评分预测1周内严重急性肾损伤或死亡。
  • 联合上述预测因子使风险比从2.17增至4.14再至10.05,联合越多风险分层越高。
  • 在1期急性肾损伤时,尿[TIMP-2]•[IGFBP7]>2.0与9个月死亡或透析风险增加相关,即使7天内未进展至2-3期。
  • 达到主要终点的患者更可能为外科患者,非肾脏APACHE III评分更高,慢性肾病更多。

适用人群与场景

  • 无急性肾损伤KDIGO 2期或3期的患者。

诊断标准与关键阈值

  • 严重急性肾损伤定义为KDIGO 3期,即需要肾脏替代治疗或尿量、血肌酐或两者变化。
  • 尿[TIMP-2]•[IGFBP7]阈值>2.0。
  • 急性肾损伤1期依据尿量、血肌酐或两者判定。

研究设计与关键结果

  • 研究类型为前瞻性国际Sapphire研究的事后分析,纳入无急性肾损伤KDIGO 2期或3期的患者,主要终点为1周内严重急性肾损伤或死亡,79例达到主要终点。
  • 达到主要终点的患者更可能为外科患者,非肾脏APACHE III评分更高,慢性肾病更多。
  • 1期尿量、血肌酐及尿[TIMP-2]•[IGFBP7]>2.0均独立于非肾脏APACHE III评分预测主要终点。
  • 联合预测因子使风险比从2.17增至4.14再至10.05。
  • 在1期急性肾损伤时,尿[TIMP-2]•[IGFBP7]>2.0与9个月死亡或透析风险增加相关,即使7天内未进展至2-3期。

证据类型、等级与局限

  • 证据类型:前瞻性国际研究的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在无KDIGO 2-3期急性肾损伤患者中,联合尿[TIMP-2]•[IGFBP7]>2.0与1期尿量或血肌酐标准可改善对1周内严重急性肾损伤或死亡的risks分层。
  • 对1期急性肾损伤患者,即使7天内未进展至2-3期,尿[TIMP-2]•[IGFBP7]>2.0提示9个月死亡或透析风险增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Decreased urine output and/or increased serum creatinine may herald the development of acute kidney injury or reflect normal physiology. In this secondary analysis of the Sapphire study, we examined biomarkers of cell cycle arrest in the settings of oliguria and/or azotemia to improve risk assessment when used with conventional indices in predicting severe acute kidney injury (Kidney Disease: Improving Global Outcomes 3 defined by the need for renal replacement therapy or changes in urine output, serum creatinine or both) or death.

DESIGN: Prospective, international, Sapphire study.

SETTING: Academic Medical Center.

PATIENTS: Patients without acute kidney injury Kidney Disease: Improving Global Outcomes stage 2 or 3.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The primary endpoint being development of severe acute kidney injury or death within 1 week. Secondary analysis examined the relationship between tissue inhibitor of metalloproteinases-2 ([TIMP-2]) and insulin growth factor binding protein 7 ([IGFBP7]) and 9-month death or dialysis conditioned on progression to stage 2-3 acute kidney injury within 1 week. Seventy-nine patients reached the primary endpoint and were more likely to be surgical, with higher nonrenal Acute Physiology and Chronic Health Evaluation III scores and more chronic kidney disease. Stage 1 urine output, serum creatinine, and urinary [TIMP-2]•[IGFBP7] greater than 2.0 were all predictive of progression to the primary endpoint independent from nonrenal Acute Physiology and Chronic Health Evaluation III score. Combinations of predictors increased the hazard ratios considerably (from 2.17 to 4.14 to 10.05, respectively). In the presence of acute kidney injury (stage 1), [TIMP-2]•[IGFBP7] greater than 2.0 leads to an increased risk of death or dialysis at 9 months even in the absence of progression of acute kidney injury (stage 2-3) within 7 days.

CONCLUSIONS: Cell cycle arrest biomarkers, TIMP-2 and IGFBP7, improve risk stratification for severe outcomes in patients with stage 1 acute kidney injury by urine output, serum creatinine or both, with risk increasing with each acute kidney injury indicator. Longer term outcomes demonstrate that the associated risks of a [TIMP-2]•[IGFBP7] greater than 2.0 is equivalent to acute kidney injury progression even where no progression from stage 1 acute kidney injury is observed.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Joannidis M, Forni LG, Haase M, et al. Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury. Crit Care Med. 2019. PMID: 31343478. doi:10.1097/CCM.0000000000003907

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。